Business Context and Reporting Period
Company: Longeveron Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 19, 2025
Reporting Period: Event-based (September 19, 2025)
Business Overview: Longeveron Inc. is a Delaware corporation focused on the clinical and regulatory development of laromestrocel for various disease states, including Hypoplastic Left Heart Syndrome, Alzheimer's Disease, and Pediatric Dilated Cardiomyopathy. The company is classified as an Emerging Growth Company.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial data points relate to a new capital raising facility:
- Offering Capacity: Up to $10,700,000 in aggregate market value of Class A Common Stock eligible for sale.
- Sales Commission: 3.0% of the gross sales price of shares sold.
- Reimbursable Expenses: Up to $100,000 for legal fees and expenses incurred by the sales agent (H.C. Wainwright & Co., LLC), plus specific per-session due diligence fees ($5,000 for 10-K updates; $3,500 for 10-Q updates).
Material Changes
The material change reported is the entry into a definitive agreement on September 19, 2025:
- At-The-Market (ATM) Offering Agreement: Longeveron entered into an agreement with H.C. Wainwright & Co., LLC to sell shares of its Class A Common Stock from time to time through an "at the market offering" program.
- Registration: The offering is based on a shelf registration statement (Form S-3) declared effective on April 4, 2025, with a prospectus supplement dated September 19, 2025.
- Flexibility: The company retains the right to designate sale parameters (number of shares, timing, price floors) and may suspend or terminate the offering at any time. No shares are obligated to be sold.
Guidance, Outlook, and Risks
Use of Proceeds: The company intends to use net proceeds for the ongoing clinical and regulatory development of laromestrocel, obtaining regulatory approvals, capital expenditures, working capital, and general corporate purposes.
Management Commentary: Management emphasizes that there is no assurance that any shares will be sold, nor regarding the price, number of shares, or timing of sales. The agreement allows for sales on Nasdaq, other trading markets, or through privately negotiated transactions.
Risks and Contingencies:
- Dilution: The offering may have a dilutive impact on existing investors.
- Capital Needs: The company faces risks regarding its ability to continue as a going concern and the sufficiency of existing cash to fund future operations.
- Development Risks: Success depends on clinical trial results, regulatory approvals, and the ability to scale production.
- Market Conditions: Sales are subject to market conditions and the company's ability to access capital.
Investor Verification Checklist
- Verify the current cash position and runway in the most recent Form 10-Q or 10-K to assess immediate liquidity needs.
- Review the full text of the ATM Agreement (Exhibit 1.1) for specific limitations on daily sales volumes or price floors.
- Monitor future filings for actual sales activity under the ATM program and the resulting dilution to share count.
- Check for updates on the clinical trial status of laromestrocel, as this drives the primary use of proceeds.
- Confirm the company's status as an Emerging Growth Company and any associated reporting exemptions.